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Abstract
Background: Exosomes are carriers of intercellular information and regulate the tumor microenvironment. They
play an important role in drug resistance by transporting RNA molecules and proteins. However, their effects on
sorafenib resistance in hepatocellular carcinoma (HCC) are not completely understood.
Methods: Exosomes were isolated from two invasive hepatoma cell lines (MHCC-97 L and MHCC-97H), and their
roles in regulating sorafenib resistance in liver cancer cells as well as the underlying molecular mechanisms were
determined. The exosomes were analyzed by TEM (transmission electron microscopy), DLS (dynamic light
scattering) and Western blotting. Cell viability, cell death and the effects of exosomes on the HGF/c-Met/Akt
signaling pathway in cancer cells were analyzed by MTT assays, FACS analysis and Western blotting, respectively.
Moreover, the effects of exosomes on sorafenib resistance in vivo were investigated using a subcutaneous
transplantation tumor model in athymic nude mice.
Results: Exosomes derived from HCC cells were of the expected size and expressed the exosomal markers CD9 and
CD63. They induced sorafenib resistance in vitro by activating the HGF/c-Met/Akt signaling pathway and inhibiting
sorafenib-induced apoptosis. They also induced sorafenib resistance in vivo by inhibiting sorafenib-induced
apoptosis. Moreover, exosomes derived from highly invasive tumor cells had greater efficacy than that of exosomes
derived from less invasive cells.
Conclusions: These data reveal the important role of HCC cell-derived exosomes in the drug resistance of liver
cancer cells and demonstrate the intrinsic interaction between exosomes and their targeted tumor cells. This study
suggests a new strategy for improving the effectiveness of sorafenib in treating HCC.
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Background
Hepatocellular carcinoma (HCC) is the fifth most com-
mon cancer and second leading cause of cancer-related
deaths worldwide, resulting in 700,000 deaths annually
[1]. Currently, surgical resection is the major treatment
modality for early-stage liver cancer [2]; however, most
patients are diagnosed in the advanced stage when treat-
ments have little effect. Currently, the 5-year survival
rate of patients with HCC is less than 20 % [3].
Phase III clinical trials showed that sorafenib, a multi-
target tyrosine kinase inhibitor that decreases tumor cell
proliferation and angiogenesis [4, 5], improved the
overall survival of patients with advanced HCC [6].
Therefore, in 2007, it was approved by the US Food and
Drug Administration as a molecular targeted drug for
unresectable liver cancer. Although sorafenib is currently
the only medication approved for the treatment of liver
cancer, its therapeutic effects are affected by several
signaling pathways, such as the reactivation of ERK
signaling and inhibition of MAPK [7, 8]. Previous studies
have suggested that gastrointestinal stromal tumor cell-
derived exosomes contain oncogenic KIT, and their
transfer and uptake by the surrounding smooth muscle
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cells led to enhanced AKT and MAPK signaling and
enhanced tumor cell invasion [9].
Exosomes play important roles in the exchange of
biological information as substance transport carriers and
in regulation of the cellular microenvironment by deliver-
ing a variety of biological molecules, including mRNAs,
miRNAs, and proteins [10–13]. Tumor cell-derived
exosomes are involved in the regulation of the epithelial-
mesenchymal transition, tumor angiogenesis, tumor
metastasis, and radioresistance [14–17]. Docetaxel and
cisplatin promote the secretion of exosomes from tumor
cells; the exosomes alter drug sensitivity by releasing
molecules such as mRNAs and miRNAs into neighboring
cells [18, 19]. Safei et al. [20] found that cisplatin-resistant
ovarian cancer cells discharged anticancer drugs through
exosomes and expressed higher levels of the transporter
proteins MRP2, ATP7A and ATP7B than those of
cisplatin-sensitive cells, suggesting that exosomes play a
key role in resistance to chemotherapy. However, whether
HCC cell-derived exosomes are involved in sorafenib re-
sistance in liver cancer cells and the potential underlying
mechanisms are currently unclear.
In this study, we investigated whether HCC cell-
derived exosomes mediate sorafenib resistance in HCC
cells and determined the potential molecular mecha-
nisms underlying this process. We found that HCC cell-
derived exosomes enhanced sorafenib resistance in liver
cancer in vitro by inhibiting sorafenib-induced apoptosis
via activation of the HGF/c-Met/Akt signaling pathways.
These findings reveal the important role of HCC cell-
derived exosomes in the drug resistance of liver cancer
cells and demonstrate the intrinsic interaction between
exosomes and their targeted tumor cells. The results of
this study may provide a new strategy for improving the
effectiveness of sorafenib in treating liver cancer.
Methods
Cell lines and cell culture
The human HCC cell line SMMC-7721 was purchased
from the Cell Bank of the Chinese Academy of Sciences
(Shanghai, China), and the MHCC-97H, MHCC-97 L and
LO2 cell lines were obtained from the Liver Cancer Insti-
tute, Fudan University (Shanghai, China). SMMC-7721,
MHCC-97H and MHCC-97 L cells were cultured in
complete DMEM containing 10 % fetal bovine serum
(FBS) and penicillin (100 U/mL). LO2 cells were cultured
in RPMI-1640 medium containing 10 % FBS, penicillin
(100 U/mL), and streptomycin (100 μg/mL). All cells were
incubated at 37 °C in humidified air with 5 % CO2.
Extraction of exosomes
MHCC-97H, MHCC-97 L and LO2 cell lines were cul-
tured in media with 10 % exosome-free FBS (by ultra-
centrifugation overnight). After 48 h, cell culture media
were collected, and exosomes were isolated from the
supernatant by differential centrifugation as previously
described [21]. Finally, the protein content of the
concentrated exosomes was determined using a BCA
protein assay kit (Thermo Scientific, USA). CD9, CD63
and GAPDH (antibodies for CD9, CD63 and GAPDH
were obtained from Cell Signaling Technology, Beverly,
MA, USA) expressions were measured using Western
blot analyses. The aliquots were stored at -80 °C.
Transmission electron microscopy (TEM) and size
distribution analysis
The extracted pellets were observed by TEM as previ-
ously described [22]. Approximately 10 μL of purified
exosomes was fixed in 1 % glutaraldehyde for 10 min,
washed, and contrasted in 2 % uranyl acetate. Images
were obtained by TEM (JEM-2100, Jeol, Japan). Scan-
ning ion occlusion sensing analysis was performed using
a Zetasizer Nano ZS90 instrument (Malvern, UK) ac-
cording to the manufacturer’s instructions. Isolated exo-
some samples were resuspended in PBS. All samples
were measured with parameters of 44.5 mm and 0.64 V
voltage using NP100 membranes. Samples were cali-
brated by CPC100 standard particles diluted 1000-fold
under identical settings.
Animal model
All animal procedures were performed according to na-
tional guidelines and approved by the Animal Care Eth-
ics Committee of Nanjing Drum Tower Hospital.
Twenty-five male BALB/c nu/nu mice (4–6 weeks old)
were purchased from the Laboratory Animal Center of
Shanghai, Academy of Science. First, all mice received
subcutaneous injections of SMMC-7721 cells in the
right armpit after infiltration anesthesia with lidocaine
(0.25 %, Nanjing Drum Tower Hospital) (1 × 107 cells in
200 μL PBS per mouse). When the tumors reached a
volume of 50–100 mm3 (15 days after subcutaneous in-
jections of tumor cells), twenty-five mice were randomly
divided into five groups (n = 5, the control group, sorafe-
nib group, sorafenib + LO2-exosome group, sorafenib +
MHCC-97 L-exosome group, and sorafenib +MHCC-
97H-exosome group). The sorafenib group was intraper-
itoneally injected with sorafenib (100 mg/kg, Selleck,
USA) daily for 10 days. The sorafenib + LO2-exosome
group, sorafenib +MHCC-97 L-exosome group, and so-
rafenib +MHCC-97H-exosome group were intraperito-
neally injected with sorafenib (100 mg/kg, Selleck, USA)
daily and subcutaneously injected with LO2, MHCC-
97 L and MHCC-97H cell-derived exosomes (100 μg
total protein in 100 μL volume, in the vicinity of the sub-
cutaneous tumors), respectively, every day for 10 days.
The control group was intraperitoneally injected with
0.4 % dimethyl sulfoxide (DMSO) in PBS (the vehicle for
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sorafenib) and subcutaneously injected with PBS (the
vehicle for exosome) daily for 10 days. The mice were
examined every 2 days, and all mice sacrificed by
cervical dislocation under general anesthesia with chloral
hydrate (5 %, 100 μL/10 g) 25 days after the subcutane-
ous injections of tumor cells.
Cell viability analysis
Cell viability was monitored using MTT assays. Briefly,
5 × 103 cells were cultured on 96-well plates. After incu-
bation with sorafenib alone or sorafenib and exosomes
for 24 or 48 h, 20 μL MTT solution (0.5 %) was added
to the medium and incubated for 4 h. Then, the medium
was removed, and 150 μL DMSO was added to each well
to dissolve the insoluble formazan product. The absorb-
ance of the colored solution was measured at 490 nm
with a spectrophotometer. All of the experiments were
performed in triplicate.
Western blot analysis
HCC cells were lysed with RIPA peptide lysis buffer
(Beyotime Biotechnology, China) containing 1 % prote-
ase inhibitors (Thermo Scientific, USA). Equal amounts
of proteins were loaded and resolved using 10 % sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE). Antibodies for CD9, CD63, GAPDH, caspase-9,
caspase-3, PARP, c-Met, p-Met, AKT, p-Akt, VEGFR2
and p-VEGFR2 were obtained from Cell Signaling Tech-
nology (Beverly, MA, USA). The Met inhibitor crizotinib
(PF-02341066) and the p-Akt inhibitor MK-2206 2HCl
were purchased from Selleck (Selleck Chemicals, China).
After incubation with horseradish peroxidase-conjugated
secondary antibodies, protein bands were visualized
using enhanced chemiluminescence (Millipore, USA).
Fluorescence microscopy analysis of exosome
internalization
MHCC-97H-derived exosomes were labeled with CM-
DIL (Sigma-Aldrich, St. Louis, MO, USA) as follows. Two
microliters of CM-DIL was added to 100 μg of MHCC-
97H-derived exosomes in a total of 1 mL of diluent and
incubated for 15 min at room temperature, and the mix-
ture was added to 18 mL of PBS and centrifuged at
120,000 g for 2 h at 4 °C. The supernatant was removed,
and the pellet was resuspended in 20 mL of PBS and cen-
trifuged at 120,000 g for 2 h at 4 °C. The pellet containing
CM-DIL-labeled exosomes was resuspended in 200 μL of
PBS medium. SMMC-7721-GFP cells were cultured in a
four-chamber slide to 80 % confluency. The medium was
added with PBS medium containing CM-DIL-labeled exo-
somes, and cells were incubated for 4 h at 37 °C in 5 %
CO2. After incubation, the cells were washed twice with
PBS and fixed in polyformaldehyde for 10 min. The slide
was mounted with ProLong Gold Antifade Reagents, and
internalization of the exosomes was analyzed using fluor-
escence microscopy.
TUNEL assay
Subcutaneous tumor samples from nude mice were
paraffin-sectioned by routine methods. Apoptotic cells
were visualized using terminal deoxynucleotidyl
transferase-mediated dUTP nick end labeling (TUNEL)
assays. The TUNEL procedure was performed using an
in situ cell death detection kit (Keygentec, KGA7025,
China) according to the manufacturer’s instructions.
Briefly, the fixed cells were incubated in 20 mg/mL pro-
teinase K for 30 min at room temperature, followed by
incubation with equilibration buffer for 10 s. The cells
were washed with PBS and incubated with streptavidin-
FITC at 37 °C for 1 h in a humidified chamber. Then,
the cells were washed with PBS again and incubated
with anti-digoxigenin conjugate (rhodamine antibody)
and counterstained with DAPI. The microscopic images
of the cells were visualized by fluorescence microscopy
(BX41, Olympus, Japan).
Enzyme-linked immunosorbent assay (ELISA)
The concentration of hepatocyte growth factor (HGF) in
the cellular supernatant was detected using a human
HGF ELISA kit (ExCell, Shanghai, China) following the
manufacturer’s instructions. Briefly, after the cells were
treated with sorafenib and HCC cell-derived exosomes
for 48 h, the media was collected and centrifuged at
5000 rpm for 5 min. Total media with 10 % FBS was
used as the control.
Statistical analysis
All data are expressed as the mean ± SD from three indi-
vidual experiments. Differences between groups were de-
termined using Student’s t-test or analysis of variance
(ANOVA). P values less than 0.05 were considered sta-
tistically significant.
Results
Extraction and characterization of HCC cell-derived
exosomes
To determine the effects of exosomes from different
sources on sorafenib resistance in HCC cells, we first
used ultracentrifugation to isolate exosomes from the
supernatants of two hepatoma cell lines (MHCC-97H
and MHCC-97 L) with different invasive potential and a
non-invasive immortalized liver cell line (LO2). MHCC-
97H has a higher invasive potential than that of MHCC-
97H, and LO2 is a normal non-invasive liver cell line
[23]. The exosomes were round in shape with diameters
of 40–150 nm, as determined by TEM and DLS (Nano-
ZS90, Malvern) (Fig. 1a, b), and expressed the exosomal
markers CD9 and CD63 (Fig. 1c).
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HCC cell-derived exosomes can be taken up and internal-
ized by hepatoma cells
To examine the potential uptake and internalization of
exosomes by SMMC-7721 cells, we labeled exosomes
derived from MHCC-97H cells with a fluorescent dye, CM-
DIL, as described in Materials and Methods. CM-DIL-
labeled exosomes were incubated with SMMC-7721-GFP
cells for 4 h, and localization of the exosomes was assessed
by fluorescence microscopy (Fig. 2). CM-DIL-labeled exo-
somes were internalized as endosome-like vesicles in the
cytoplasm of SMMC-7721-GFP cells (Fig. 2c, d). These
studies indicate that HCC cell-derived exosomes can be
taken up and internalized by HCC cells.
HCC cell-derived exosomes induce sorafenib resistance in
hepatoma cells in vivo
To determine whether HCC cell-derived exosomes can in-
duce sorafenib resistance in liver cancer in vivo, we estab-
lished a subcutaneous xenograft model in nude mice and
injected sorafenib together with LO2-, MHCC-97 L-, or
MHCC-97H-derived exosomes into the mice. As shown
in Fig. 3a, the tumors in mice treated with sorafenib plus
MHCC-97 L- or MHCC-97H-derived exosomes were
significantly larger than those in mice treated with sorafe-
nib alone or sorafenib plus LO2-derived exosomes,
indicating that invasive HCC cell-derived exosomes inhibit
the therapeutic effects of sorafenib and promote tumor
growth. Figure 3b-c shows the tumor volume and weight
of each group. The tumor volume and weight of mice
treated with sorafenib plus exosomes derived from
MHCC-97H cells were approximately 5-fold greater than
those in mice treated with sorafenib alone (Fig. 3b, c).
Fig. 3c also demonstrates that tumors in mice treated with
sorafenib plus MHCC-97H-derived exosomes were sig-
nificantly larger than those in mice treated with sorafenib
plus MHCC-97 L-derived exosomes, indicating that
exosomes derived from a more invasive HCC cell line
showed greater inhibition of the chemotherapeutic effects
of sorafenib and stronger promotion of tumor growth that
those of exosomes derive from less invasive cell lines.
Fig. 1 Characterization of exosomes derived from different cell lines. a TEM confirmed that the final pellets from ultracentrifugation were
exosomes (scale bar, 100 nm). b Size distribution analysis of purified exosomes by DLS (Nano-ZS90, Malvern). c Exosomal markers (CD9, CD63)
were analyzed using Western blotting and are present in cells and exosomes (GAPDH was used as an internal reference)
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Fig. 2 Internalization of MHCC-97H-derived exosomes in SMMC-7721-GFP cells. SMMC-7721-GFP cells in culture were incubated with
MHCC-97H-derived exosomes labeled with CM-DIL (red). Cells were fixed with polyformaldehyde and mounted with ProLong Gold Antifade Reagent,
as described in Materials and Methods. Low-magnification images of SMMC-7721-GFP cells incubated with exosomes (a, b, c). High-magnification
images of SMMC-7721-GFP cells incubated with exosomes (d). MHCC-97H-derived exosomes were shown to be internalized in the cytoplasm of
SMMC-7721-GFP cells
Fig. 3 HCC cell-derived exosomes induce resistance to sorafenib in hepatoma carcinoma cells in vivo. a Tumors from mice treated with PBS
(Control), sorafenib (Sora), sorafenib + LO2-exosomes (Sora + LO2 exo), sorafenib + MHCC-97 L-exosomes (Sora + 97 L exo), and sorafenib +
MHCC-97H-exosomes (Sora + 97H exo) at the end of the experiment. b Tumor growth curves in mice treated with PBS (Control), sorafenib (Sora),
sorafenib + LO2-exosomes (Sora + LO2 exo), sorafenib + MHCC-97 L-exosomes (Sora + 97 L exo), and sorafenib + MHCC-97H-exosomes (Sora + 97H
exo) (n = 5, * P <0.05, ** P <0.01). Treatment was initiated when tumors reached a volume of 50–100 mm3 (15 days after subcutaneous injections
of tumor cells). c The mean weight of the tumors from mice treated with PBS (Control), sorafenib (Sora), sorafenib + LO2-exosomes (Sora + LO2
exo), sorafenib + MHCC-97 L-exosomes (Sora + 97 L exo), and sorafenib + MHCC-97H-exosomes (Sora + 97H exo) at the end of the experiment
(n = 5, * P <0.05, ** P <0.01)
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Tumor volume or tumor weight in mice treated with soraf-
enib alone showed no significant difference from that in
mice treated with sorafenib plus LO2-derived exosomes.
HCC cell-derived exosomes induce sorafenib resistance of
hepatoma cells in vitro
We used MTT assays to determine the half maximal in-
hibitory concentration (IC50) of sorafenib in different
hepatoma cell lines. The results showed SMMC-7721 cells
were more sensitive to sorafenib than MHCC-97 L and
MHCC-97H cells, and MHCC-97H cells were the least
sensitive to sorafenib among the three cell lines (Fig. 4a).
To determine if HCC cell-derived exosomes could
induce sorafenib resistance in the SMMC-7721 HCC cell
line in vitro, we used MTT assays to first confirm that
sorafenib dose-dependently inhibited cell viability (Fig. 4b).
Then, we cultured the cells in medium supplemented with
sorafenib plus exosomes from different sources and exam-
ined cell viability again. We found that the addition of
MHCC-97H- or MHCC-97 L-derived exosomes signifi-
cantly inhibited the sorafenib-induced reduction of cell
viability, but addition of LO2-derived exosomes did not
have this effect, indicating that invasive HCC cell-derived
exosomes inhibit the therapeutic effects of sorafenib and
promote tumor cell growth. Furthermore, this effect was
more dramatic with MHCC-97H- compared to that of
MHCC-97 L-derived exosomes (P <0.05, Fig. 4b), indicat-
ing that more invasive HCC cell-derived exosomes show
stronger promotion of HCC cell proliferation and
inhibition of the chemotherapeutic effects of sorafenib.
Moreover, MTT assays showed that the IC50 of sorafenib
in SMMC-7721 cells treated with MHCC-97H- or
Fig. 4 HCC cell-derived exosomes induced sorafenib resistance in SMMC-7721 cells. a IC50 values of sorafenib in SMMC-7721, MHCC-97 L and
MHCC-97H cells determined by MTT assay (* P <0.05). The cells were treated with sorafenib for 48 h, and the sensitivity of SMMC-7721 cells to
sorafenib was higher than that of MHCC-97 L and MHCC-97H cells (* P <0.05). b Cell viability was assessed by MTT assays. HCC cell-derived
exosomes attenuated sorafenib-induced cell suppression. SMMC-7721 cells were treated with sorafenib at different concentrations with or without
exosomes for 48 h (* P <0.05). c IC50 values for sorafenib in SMMC-7721 cells with or without exosomes determined by MTT assays. The
SMMC-7721 cells were treated with sorafenib at different concentrations with or without exosomes for 48 h. The IC50 of sorafenib in SMMC-7721
cells in the HCC-derived exosome groups was notably elevated compared to that of the sorafenib alone group (* P <0.05; ** P <0.01).
d MHCC-97H derived exosomes prevented the reduction of SMMC-7721 viability induced by sorafenib in a time- and dose-dependent manner
(* P <0.05). Cell viability was assessed by MTT assays. The SMMC-7721 cells were treated with sorafenib at 10 μM with or without exosomes at
different concentrations for 24 or 48 h
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MHCC-97 L-derived exosomes was notably elevated com-
pared to that in the sorafenib alone group or the LO2-exo-
some group, and the IC50 of sorafenib in SMMC-7721
cells treated with MHCC-97H-derived exosomes was sig-
nificantly higher than that in the MHCC-97 L-derived
exosome group (P <0.05, Fig. 4c). Moreover, MHCC-97H-
derived exosomes prevented the sorafenib-induced
reduction of cell viability in a time- and dose-dependent
manner (Fig. 4d).
HCC cell-derived exosomes inhibit sorafenib-induced
apoptosis
To determine whether HCC cell-derived exosomes can
affect sorafenib-induced cell apoptosis, we assessed
sorafenib-induced apoptosis in hepatoma cells in the
presence or absence of HCC cell-derived exosomes.
SMMC-7721 cells were exposed to sorafenib for 48 h,
and the percentage of apoptotic cells was analyzed using
Annexin V-FITC/PI apoptosis staining. The apoptotic
rate of SMMC-7721 cells in the sorafenib plus MHCC-
97H- or MHCC-97 L-derived exosome groups was
35.42 % ± 2.82 % and 47.33 % ± 7.05 %, respectively,
which was significantly lower than that in the sorafenib
alone (60.48 % ± 9.42 %) or sorafenib plus LO2-derived
exosome groups (53.96 % ± 8.64 %) (Fig. 5a, b).
Moreover, to further elucidate the effect of HCC cell--
derived exosomes on apoptosis in vivo, we used TUNEL
staining. The results demonstrated that the number of
apoptotic cells in the subcutaneous tumor tissues signifi-
cantly increased after tumors were treated with sorafenib
alone or sorafenib plus LO2-derived exosomes (25.41 ±
2.71, 23.61 ± 3.03 versus 3.65 ± 0.59, Fig. 6a, b). However,
co-treatment with HCC cell-derived exosomes signifi-
cantly reduced the apoptotic rate (10.64 % ± 2.44 %,
18.38 % ± 1.28 % versus 25.41 % ± 2.71 %, Fig. 6a, b).
Furthermore, compared to the apoptotic rate in the
sorafenib plus MHCC-97 L-derived exosome group, the
apoptotic rate in the sorafenib plus MHCC-97H-derived
exosome group was significantly higher (Figs. 5b and 6b).
Then, we assessed the effects of sorafenib alone or
sorafenib plus exosomes from different sources on the
levels of apoptotic proteins, such as cleaved caspase-9,
caspase-3, and PARP, in SMMC-7721 cells. Treatment
with sorafenib plus MHCC-97H- or MHCC-97 L-de-
rived exosomes significantly reduced the levels of
cleaved caspase-9, caspase-3, and PARP compared with
Fig. 5 HCC cell-derived exosomes reverse sorafenib-induced apoptosis in hepatoma carcinoma cells in vitro. a Flow cytometric analyses of
apoptotic cells ex vivo. The SMMC-7721 cells were exposed to sorafenib alone or sorafenib and exosomes for 48 h, collected and subjected to
Annexin V/PI double staining, followed by FACS analyses. For each assay, 10,000 cells were analyzed. b The quantitative data are presented as the
mean ± SD of triplicate experiments (* P <0.05)
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that in the sorafenib alone group or sorafenib plus LO2-
exosome group (Fig. 7), indicating that HCC cell-derived
exosomes can partially reverse sorafenib-induced apop-
tosis. Interestingly, the effects of MHCC-97H-derived
exosomes were more dramatic than those of MHCC-
97 L-derived exosomes. Taken together, these results
suggested that HCC cell-derived exosomes could reverse
the induction of apoptosis by sorafenib in HCC, and
more invasive HCC cell-derived exosomes showed a
greater ability to reverse sorafenib-induced apoptosis.
HCC cell-derived exosomes affect sorafenib resistance via
the HGF/c-Met/Akt pathway
To explore the possible mechanisms by which HCC
cell-derived exosomes induce sorafenib resistance, we
also examined HGF levels in the supernatants of cells
from different treatment groups using ELISAs. Previous
reports have shown that exosomes can induce erlotinib
resistance in breast cancer. Our results indicated that
treatment with HCC cell-derived exosomes for 48 h
increased HGF levels in the cell culture supernatant
compared to those of the control group, and MHCC-
97H-derived exosomes caused the most significant
effects (P <0.05, Fig. 8a). Western blot analysis showed
that treatment with MHCC-97H- and MHCC-97 L-de-
rived exosomes increased the levels of phosphorylated
Met, Akt and VEGFR2 compared to those of the
treatment with sorafenib alone or sorafenib plus LO2-
exosome groups (Fig. 8b). However, the increase in
phosphorylated c-Met and Akt induced by MHCC-97H-
Fig. 6 HCC cell-derived exosomes reverse sorafenib-induced apoptosis in hepatoma carcinoma cells in vivo. a Tumors from mice treated with
PBS (Control), sorafenib (Sora), sorafenib + LO2-exosomes (Sora + LO2 exo), sorafenib + MHCC-97 L-exosomes (Sora + 97 L exo), and sorafenib +
MHCC-97H-exosomes (Sora + 97H exo) were paraffin-embedded and sectioned, followed by staining of apoptotic cell by using TUNEL assays.
b The number of TUNEL-positive cells notably decreased in the sorafenib + MHCC-97 L-exosome or sorafenib + MHCC-97H exosome groups
compared to the those of the sorafenib alone or sorafenib + LO2-exosome groups (* P <0.05)
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and MHCC-97 L-derived exosomes was weakened by
the c-Met inhibitor crizotinib (Fig. 8c), and the increase
in phosphorylated Akt induced by MHCC-97H- and
MHCC-97 L-derived exosomes was also reduced by the
p-Akt inhibitor MK-2206 (Fig. 8d).
Discussion
The tumor microenvironment plays an important role in
drug resistance and tumor recurrence [24, 25], which is
a major obstacle to treating advanced tumors. As a
transport carrier of various biological molecules, exo-
somes and exosomal active factors (proteins, mRNAs,
miRNAs and others) participate in the regulation of the
tumor microenvironment [14, 26]. Thus, the role of exo-
somes as biological delivery vehicles in drug resistance is
of considerable interest [27]. Previous studies suggested
that a combination of guggulsterone and bexarotene
reduced cellular levels of breast cancer resistance protein
to 20 % of that of the control cells by inducing its associ-
ation and secretion with exosomes [28]. Shao et al. [29]
analyzed MGMT and APNG mRNA levels in enriched
tumor exosomes obtained from blood, and they found
that exosomal mRNA levels of these enzymes correlated
well with levels found in parental cells and that the
levels changed considerably during treatment of seven
glioblastoma multiforme patients. These markers may be
used to predict drug response in glioblastoma multi-
forme patients [29]. Moreover, drug-resistant breast
cancer cells may spread resistance to sensitive cells by
releasing exosomes containing specific miRNAs (miR-
4443, miR-574-3p, and others) [30].
Exosomes derived from the serum of prostate cancer
patients influenced cellular proliferation, invasion and
response to docetaxel, which may be partly due to
exosomal MDR-1/Pgp transfer [18]. Bone marrow stro-
mal cells and multiple myeloma cells could mutually
exchange exosomes carrying specific cytokines, which
increased multiple myeloma cell growth and induced
drug resistance to bortezomib [31]. In addition,
exosomal lncRNA has recently attracted more attention.
Takahashi et al. [32] found that specific exosomal
lncRNA mediators, such as lincRNA-ROR, are involved
in modulation of hepatoma cellular responses to sorafe-
nib. Moreover, lincRNA-VLDLR could be transferred by
HCC cell-derived exosomes and modulate resistance to
anti-cancer agents, such as sorafenib, camptothecin, and
doxorubicin, in recipient cancer cells [33]. Here, we
showed for the first time that different invasive HCC
cell-derived exosomes can regulate the sensitivity of
HCC to sorafenib, in part by reversing sorafenib-induced
apoptosis (Figs. 5, 6 and 7). Moreover, elevated
expression of a cytokine (HGF) may be an important
mechanisms underlying HCC resistance to sorafenib
(Fig. 8). HCC cell-derived exosomes transfer of the
soluble factor HGF may contribute to the regulation of
the tumor microenvironment [34].
The HGF receptor, c-Met, is a proto-oncogene [5, 35].
Studies have found that its overexpression in tumor cells
is an important mechanism of sorafenib resistance, and
the c-Met-targeting drug PHA665752 inhibits its expres-
sion in various HCC cell lines. In vivo experiments also
confirmed that inhibition of c-Met in HCC cells could
increase their sensitivity to therapeutic agents [36]. Our
previous study found that hepatic stellate cells and their
conditioned medium promoted cell proliferation and
enhanced the sorafenib resistance of liver cancer cells
[37]. In this study, we found that treatment of HCC cells
with MHCC-97 L and MHCC-97H cell-derived
exosomes increased HGF levels in the medium, which
further activated p-Met in liver cancer cells, ultimately
leading to activation of its key downstream protein,
p-Akt (Fig. 8a, b). The effect induced by HCC cell-der-
ived exosomes was reversed by the c-Met inhibitor cri-
zotinib and the p-Akt inhibitor MK-2206 in recipient
cells. Both inhibitors indirectly or directly reduced the
phosphorylation of Akt (Fig. 8c, d). Our studies
confirmed that HCC cell-derived exosomes induced
sorafenib resistance by increasing HGF levels in the
tumor microenvironment and activating the c-Met/Akt
pathway in vitro, suggesting that HGF/c-Met may be an
important target for improving sorafenib resistance of
HCC. Our study further revealed that HCC cell-derived
exosomes promoted sorafenib resistance in liver cancer,
and exosomes derived from highly invasive tumors could
trigger stronger drug resistance. Mian et al. characterized
the exosomal RNA and proteome contents derived from
three HCC cell lines (HKCI-C3, HKCI-8 and MHCC-
Fig. 7 HCC cell-derived exosomes decreased cleavage of caspases and
PARP. MHCC-97H-derived exosomes were more effective than
MHCC-97 L-exosomes. Cell lysates were subjected to Western blotting
after sorafenib alone or sorafenib and exosome administration for 48 h
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97 L) using Ion Torrent sequencing and mass spectrom-
etry. RNA deep sequencing and proteomic analysis re-
vealed that exosomes derived from different metastatic
HCC cell lines had different levels of proteins and pro-
tumorigenic RNAs. Thus, we hypothesized that exosomes
from different sources contained different levels of cyto-
kines (HGF, TGFβ, and VEGF) and proteins [34], which
could be transported to recipient cells and played various
roles in the regulation of sorafenib resistance in HCC.
Moreover, differential miRNA expression in exosomes de-
rived from different cell lines should be determined using
miRNA microarrays, and the roles of these miRNAs in
sorafenib resistance of liver cancer should be explored
further.
Conclusions
In summary, this study confirmed that HCC cell-derived
exosomes can enhance sorafenib resistance in liver cancer
cells in vitro, and exosomes derived from highly invasive
tumors have greater effects than those derived from less
invasive tumors. Moreover, HCC cell-derived exosomes
exerted their functions by increasing the level of proteins
related to sorafenib resistance, protecting tumor cells from
sorafenib-induced apoptosis and activating the HGF/c-
Fig. 8 HCC cell-derived exosomes affect sorafenib resistance via the HGF/c-Met/Akt pathway. a Elevated HGF levels in the cell culture supernatant
contributed to sorafenib resistance induced by HCC cell-derived exosomes. HGF concentrations in the supernatant were determined by ELISA.
Treatment of cells with HCC cell-derived exosomes for 48 h significantly increased HGF levels in the cell culture supernatant compared to that of
the sorafenib group. The effects of MHCC-97H-derived exosomes were greater than those of MHCC-97 L-derived exosomes (* P <0.05). b HCC
cell-derived exosomes increased the level of phosphorylated Met, Akt and VEGFR2 compared with that of sorafenib alone. c The increase in
phosphorylated c-Met and Akt induced by MHCC-97H and MHCC-97 L derived exosomes was reduced by the c-Met inhibitor crizotinib (sora:
sorafenib). d The increase in the levels of phosphorylated Akt induced by MHCC-97H- and MHCC-97 L-derived exosomes was weakened by the
p-Akt inhibitor MK-2206 (sora: sorafenib)
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Met/Akt pathway in vitro. Our results suggest that HCC
cell-derived exosomes are important mediators of sorafe-
nib resistance in liver cancer cells. Targeting HCC cell--
derived exosomes or the HGF/c-Met/Akt pathway may
help improve treatment efficacy in liver cancer.
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